Advertisement


Amanda Nizam, MD, on Urothelial Carcinoma: Study Results on Enfortumab Vedotin and Avelumab

2024 ASCO GU Cancers Symposium

Advertisement

Amanda Nizam, MD, of the Cleveland Clinic, discusses results from the UNITE study, which shows patients with advanced urothelial cancer who were treated with enfortumab vedotin-ejfv (EV) after switch maintenance avelumab had outcomes consistent with data with EV in platinum- and immune checkpoint inhibitor–refractory disease (Abstract 537).



Related Videos

Prostate Cancer

Umang Swami, MD, on Prostate Cancer: Differences in Genomic, Transcriptomic, and Immune Landscape Based on Site of Metastasis

Umang Swami, MD, of Huntsman Cancer Institute at the University of Utah, describes the molecular and immunologic mechanisms of metastatic tropism in advanced prostate cancer, data that may facilitate future drug development. In patients with metastatic disease, specific sites are associated with differential overall survival, but the biological reasons have not been fully explored (Abstract 21).

Kidney Cancer

Thomas Powles, MD, on RCC: Patient-Reported Outcomes With Belzutifan vs Everolimus

Thomas Powles, MD, of Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, and Queen Mary University of London, discusses outcomes reported by patients with previously treated renal cell carcinoma (RCC), taking part in the phase III LITESPARK-005 study. Belzutifan was associated with a prolonged time to deterioration, fewer disease-specific symptoms, and better quality of life compared with everolimus (Abstract 361).

Bladder Cancer
Immunotherapy

Syed Muneeb Alam, MD, on Urothelial Carcinoma: Microsatellite Instability and Response to Immune Checkpoint Blockade

Syed Muneeb Alam, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings evaluating links among microsatellite instability status, tumor mutational burden, and response to immune checkpoint blockade in patients with microsatellite instability–high urothelial carcinoma (Abstract 536).

Prostate Cancer

Maha H.A. Hussain, MD, on Prostate Cancer: New Data on Abiraterone and Prednisone Plus Olaparib

Maha H.A. Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses phase II findings from the BRCAAway trial. This study showed that in patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM alterations, abiraterone and prednisone plus olaparib was well tolerated and resulted in a longer progression-free survival than either agent alone or sequentially.

Kidney Cancer

Thomas Powles, MD, on Clear Cell Kidney Cancer: Overall Survival Update With Adjuvant Pembrolizumab

Thomas Powles, MD, of Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, and Queen Mary University of London, discusses overall survival results from the phase III KEYNOTE-564 study of adjuvant pembrolizumab vs placebo in patients with clear cell renal cell carcinoma (Abstract LBA359).

Advertisement

Advertisement




Advertisement